Ashley B Petrone1,2, Valerie Gionis3, Richard Giersch3, Taura L Barr3. 1. Department of Family Medicine, West Virginia University, Morgantown, WV, USA. 2. West Virginia Clinical and Translational Science Institute, Morgantown, WV, USA. 3. Valtari Bio™ Inc., Morgantown, WV, USA.
Abstract
BACKGROUND: In 2010, there were approximately 2.2 million emergency room visits associated with traumatic brain injury (TBI), with 80 percent diagnosed as mild TBI or concussion. In addition, there are a large number of TBIs, especially mild TBIs, which go either unreported by patients or initially undiagnosed by clinicians. Our team has previously identified a panel of immune-related genes that can diagnose ischemic stroke at triage, and due to shared pathophysiological mechanisms of TBI and stroke, we hypothesized that this panel of genes may also be utilized for the diagnosis of TBI. OBJECTIVES: The primary aims of this pilot study were to: (1) characterize changes in a panel of immune-related genes in TBI; (2) identify immune-related biomarkers that may be used to diagnose TBI and (3) describe the peripheral immune response following TBI. METHODS: Blood was drawn from TBI patients no later than 24 h of injury onset and matched control subjects. Real-time PCR was used to measure gene expression, and a white blood cell differential was performed to obtain neutrophil and lymphocyte percentages. RESULTS: Relative mRNA expression of ARG1, LY96, MMP9, s100a12 was significantly increased and CCR7 was significantly decreased in peripheral blood of TBI patients within 24 hours of injury compared to control subjects. We also observed a different pattern of leukocyte dynamics following TBI between mild and severe TBI. CONCLUSIONS: We have described a panel of immune-related genes that can accurately predict/diagnose TBI with higher sensitivity and specificity of other biomarkers to date.
BACKGROUND: In 2010, there were approximately 2.2 million emergency room visits associated with traumatic brain injury (TBI), with 80 percent diagnosed as mild TBI or concussion. In addition, there are a large number of TBIs, especially mild TBIs, which go either unreported by patients or initially undiagnosed by clinicians. Our team has previously identified a panel of immune-related genes that can diagnose ischemic stroke at triage, and due to shared pathophysiological mechanisms of TBI and stroke, we hypothesized that this panel of genes may also be utilized for the diagnosis of TBI. OBJECTIVES: The primary aims of this pilot study were to: (1) characterize changes in a panel of immune-related genes in TBI; (2) identify immune-related biomarkers that may be used to diagnose TBI and (3) describe the peripheral immune response following TBI. METHODS: Blood was drawn from TBI patients no later than 24 h of injury onset and matched control subjects. Real-time PCR was used to measure gene expression, and a white blood cell differential was performed to obtain neutrophil and lymphocyte percentages. RESULTS: Relative mRNA expression of ARG1, LY96, MMP9, s100a12 was significantly increased and CCR7 was significantly decreased in peripheral blood of TBI patients within 24 hours of injury compared to control subjects. We also observed a different pattern of leukocyte dynamics following TBI between mild and severe TBI. CONCLUSIONS: We have described a panel of immune-related genes that can accurately predict/diagnose TBI with higher sensitivity and specificity of other biomarkers to date.
Entities:
Keywords:
Traumatic brain injury; inflammation; neutrophil-lymphocyte ratio
Authors: Yang Tang; Huichun Xu; XinLi Du; Lisa Lit; Wynn Walker; Aigang Lu; Ruiqiong Ran; Jeffrey P Gregg; Melinda Reilly; Art Pancioli; Jane C Khoury; Laura R Sauerbeck; Janice A Carrozzella; Judith Spilker; Joseph Clark; Kenneth R Wagner; Edward C Jauch; Dongwoo J Chang; Piero Verro; Joseph P Broderick; Frank R Sharp Journal: J Cereb Blood Flow Metab Date: 2006-01-04 Impact factor: 6.200
Authors: Michael J Souter; Patricia A Blissitt; Sandralee Blosser; Jordan Bonomo; David Greer; Draga Jichici; Dea Mahanes; Evie G Marcolini; Charles Miller; Kiranpal Sangha; Susan Yeager Journal: Neurocrit Care Date: 2015-08 Impact factor: 3.210
Authors: Kerry T Donnelly; James P Donnelly; Mina Dunnam; Gary C Warner; C J Kittleson; Janet E Constance; Charles B Bradshaw; Michelle Alt Journal: J Head Trauma Rehabil Date: 2011 Nov-Dec Impact factor: 2.710
Authors: Iain D Croall; Christopher J A Cowie; Jiabao He; Anna Peel; Joshua Wood; Benjamin S Aribisala; Patrick Mitchell; A David Mendelow; Fiona E Smith; David Millar; Tom Kelly; Andrew M Blamire Journal: Neurology Date: 2014-07-16 Impact factor: 9.910
Authors: Richard P Tobin; Sanjib Mukherjee; Jessica M Kain; Susannah K Rogers; Stephanie K Henderson; Heather L Motal; M Karen Newell Rogers; Lee A Shapiro Journal: Acta Neuropathol Commun Date: 2014-10-20 Impact factor: 7.801
Authors: Diego Lozano; Gabriel S Gonzales-Portillo; Sandra Acosta; Ike de la Pena; Naoki Tajiri; Yuji Kaneko; Cesar V Borlongan Journal: Neuropsychiatr Dis Treat Date: 2015-01-08 Impact factor: 2.570
Authors: Julia Dixon; Grant Comstock; Jennifer Whitfield; David Richards; Taylor W Burkholder; Noel Leifer; Nee-Kofi Mould-Millman; Emilie J Calvello Hynes Journal: Afr J Emerg Med Date: 2020-06-16
Authors: Khashayar Mozaffari; Dillon Dejam; Courtney Duong; Kevin Ding; Alexis French; Edwin Ng; Komal Preet; Alyssa Franks; Isabelle Kwan; H Westley Phillips; Dennis Y Kim; Isaac Yang Journal: Cureus Date: 2021-08-10
Authors: Abdelrahman Y Fouda; Wael Eldahshan; S Priya Narayanan; R William Caldwell; Ruth B Caldwell Journal: Front Pharmacol Date: 2020-03-17 Impact factor: 5.810
Authors: Agata Ciechanowska; Katarzyna Popiolek-Barczyk; Katarzyna Ciapała; Katarzyna Pawlik; Marco Oggioni; Domenico Mercurio; Maria-Grazia de Simoni; Joanna Mika Journal: Pharmacol Rep Date: 2020-11-13 Impact factor: 3.024